Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2603618 and pemetrexed in advanced or metastatic NSCLC
NCT00988858Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Jul 2012
- Countries
- 4
01
Overview
A Phase 2 trial of rabusertib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Nov 2009; status: completed.
02
Drugs
rabusertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00988858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988858.